Iran Pharmaceuticals and Healthcare Report Q4 2015 57387 Now Available at LifeScienceIndustryResearch.com

Iran Pharmaceuticals and Healthcare Report Q4 2015

120 pages report Published in Sep 2015

Pharmaceuticals

Publisher: Business Monitor International

Report Description
Table of Content
Related Reports

BMI View: Iran’s pharmaceutical market holds significant potential for innovative drugmakers,
particularly with the easing of sanctions. This potential is unlikely to be realised in the near term, however,
as the government operates in favour of the well developed domestic industry.
Headline Expenditure Projections
? Pharmaceuticals: IRR60.70tn (USD2.35bn) in 2014 to IRR69.55trn (USD1.93bn) in 2015; +14.6% in
local currency terms and -17.8% in US dollar terms. Forecast upgraded slightly from previous quarter.
? Healthcare: IRR695.67trn (USD21.88bn) in 2014 to IRR792.81trn (USD22.02bn) in 2015; +14.0% in
local currency terms and +0.7% in US dollar terms. Forecast in line with previous quarter.

Table of Contents

BMI Industry View 7
SWOT 9
Political 11
Economic . 13
Operational Risk 14
Industry Forecast 16
Pharmaceutical Market Forecast 16
Table: Pharmaceutical Sales, Historical Data And Forecasts (Iran 2011-2019) 19
Healthcare Market Forecast 20
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Iran 2011-2019) 22
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Iran 2011-2019) 23
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Iran 2011-2019) 24
Prescription Drug Market Forecast . 25
Patented Drug Market Forecast . 26
Generic Drug Market Forecast 27
OTC Market Forecast 28
Pharmaceutical Trade Forecast . 29
Table: Pharmaceutical Trade Data And Forecasts (Iran 2013-2019) 32
Table: Pharmaceutical Trade Data And Forecasts local currency (Iran 2013-2019) 32
Key Risks To BMI's Forecast Scenario 33
Macroeconomic Forecasts 34
Economy To Grow Again On Sanctions Relief 34
Table: Economic Activity (Iran 2010-2019) 40
Table: GDP By Expenditure (Iran 2012-2019) 40
Industry Risk Reward Indices 42
Middle East and Africa Risk/Reward Index 42
Iran Risk/Reward Index 49
Rewards . 49
Risks 49
Market Overview 51
Industry Trends And Developments 52
Epidemiology 52
Table: HIV/AIDS Prevalence In Iran 54
Healthcare Sector . 54
Table: Healthcare Resources (Iran 2009-2014) 57
Table: Healthcare Personnel (Iran 2009-2014) 58
Table: Healthcare Activity (Iran 2009-2014) 58
Healthcare Insurance . 58
International Healthcare Collaboration . 60
Traditional Herbal Remedies 60
Research & Development . 61
Biotechnology . 62
Clinical Trials . 65
Regulatory Development 66
Intellectual Property Regime 68
Counterfeit Medicines 69
Pricing And Reimbursement . 70
Competitive Landscape . 72
Pharmaceutical Sector 72
Generic Drugmakers . 74
Table: Leading Drug Manufacturers, Iranian Year To March 20, 2009 74
Pharmaceutical Distribution 77
Table: Leading Distributors, Iranian Year To March 20 2008 79
Pharmaceutical Retail Sector 79
Company Profile 80
Amin Pharmaceutical Company . 80
Caspian Tamin Pharmaceutical Company . 82
Darou Pakhsh 85
Exir Pharmaceuticals 88
GlaxoSmithKline 90
Merck & Co 92
Novartis 94
Pars Darou 96
Pfizer 98
Pharmieco 100
Sanofi . 102
Sina Darou Pharmaceutical Company 104
Zahravi Pharmaceutical Company . 106
Demographic Forecast 109
Table: Population Headline Indicators (Iran 1990-2025) 110
Table: Key Population Ratios (Iran 1990-2025) 110
Table: Urban/Rural Population And Life Expectancy (Iran 1990-2025) 111
Table: Population By Age Group (Iran 1990-2025) 111
Table: Population By Age Group % (Iran 1990-2025) 112
Glossary . 114
Methodology 116
Pharmaceutical Expenditure Forecast Model 116
Healthcare Expenditure Forecast Model 116
Notes On Methodology 117
Risk/Reward Index Methodology 118
Index Overview 119
Table: Pharmaceutical Risk/Reward Index Indicators 119
Indicator Weightings 120

List of Tables

Table: Pharmaceutical Sales, Historical Data And Forecasts (Iran 2011-2019)
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Iran 2011-2019)
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Iran 2011-2019)
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Iran 2011-2019)
Table: Pharmaceutical Trade Data And Forecasts (Iran 2013-2019)
Table: Pharmaceutical Trade Data And Forecasts local currency (Iran 2013-2019)
Table: Economic Activity (Iran 2010-2019)
Table: GDP By Expenditure (Iran 2012-2019)
Table: HIV/AIDS Prevalence In Iran
Table: Healthcare Resources (Iran 2009-2014)
Table: Healthcare Personnel (Iran 2009-2014)
Table: Healthcare Activity (Iran 2009-2014)
Table: Leading Drug Manufacturers, Iranian Year To March 20, 2009
Table: Leading Distributors, Iranian Year To March 20 2008
Table: Population Headline Indicators (Iran 1990-2025)
Table: Key Population Ratios (Iran 1990-2025)
Table: Urban/Rural Population And Life Expectancy (Iran 1990-2025)
Table: Population By Age Group (Iran 1990-2025)
Table: Population By Age Group % (Iran 1990-2025)
Table: Pharmaceutical Risk/Reward Index Indicators

Related Reports

Lithuania Pharmaceuticals and Healthcare Report Q4 2015
BMI View: Non-communicable conditions such as cardiovascular disease and cancer will continue to be the primary contributors to Lithuania's disease burden. Although these disease dynamics will make the country attractive to innovative drugmakers, the small size of the country's population will limit the commercial opportunity. The absolute disease burden is expected to decline over the next 15 years as the standard of healthcare improves and the population contracts. Headline Expenditure Project...
Bahrain Pharmaceuticals and Healthcare Report Q4 2015
BMI View: Bahrain's government will continue in its attempts at containing the rapidly expanding cost of healthcare. Private sector engagement and increasing generic substitution will continue to be employed, although government spending on the sector will continue to increase given its importance in social stability. The uptake of compulsory health insurance and increased government spending will continue to drive growth within the pharmaceutical market, with drugmakers viewing Bahrain as a sma...
Botswana Pharmaceuticals and Healthcare Report Q1 2015
BMI View: Our outlook for the pharmaceutical and healthcare markets of Botswana is reasonably positive due to the government's increasing commitment to improve the country's healthcare sector. The country's import reliance for pharmaceuticals, coupled with the forecast depreciation of the Botswana pula will be seen as a negative for the local industry as imports will become increasingly expensive. Headline Expenditure Projections ? Pharmaceuticals: BWP1.66bn (USD198mn) in 2013 to BWP1.85bn (USD2...
Sudan and South Sudan Pharmaceuticals and Healthcare Report Q3 2015
BMI View: Due to the lack of production capacity among domestic companies, the majority of pharmaceuticals in Sudan and South Sudan will remain sourced from abroad. Over the long-term, domestic manufacturers will increase their market share, with the government placing an increasing emphasis on achieving self-sufficiency in terms of pharmaceutical production. Headline Expenditure Projections ? Pharmaceuticals: SDG2.35bn (USD402mn) in 2014 to SDG2.65bn (USD433mn) in 2015; +12.9% in local currency...
Tanzania Pharmaceuticals and Healthcare Report Q1 2015
BMI View: We expect the continuing depreciation of the Tanzanian shilling to make imports of raw materials increasingly expensive for the few remaining domestic pharmaceutical manufacturers. A tax regime that favours imports of finished pharmaceuticals and a lack of skilled labour will be detrimental to local manufacturers, and will see the country remain reliant on imported pharmaceuticals for the foreseeable future. Headline Expenditure Projections ? Pharmaceuticals: TZS693.86bn (USD429mn) in ...